One of the reasons that physicians may not be associating adverse events, like strokes, seizures, neurological issues, blood clots, etc., is that Pfizer ran almost no bloodwork during their studies. During their single phase I trial of 30 subjects they only did basic hematology and chemistry, showing transient decreases in lymphocytes. As per Good Laboratory Practices, Phase 1-3, pre and post drug bloodwork is critical and encompasses hematology, chemistry, inflammatory biomarkers, pharmacodynamics/pharmacokinetics, specialty markers like D-dimer, etc. This was not done. In their single Phase 2, which was simply the first 360 subjects enrolled, the remaining 39,640 (roughly) were considered as Phase 3, there was no blood work, other than immunogenicity, at all. How then can Pfizer or any physician know if an adverse effect is caused by the vaccine? We have no data on how the liver, kidney, vascular system, etc., is affected. Do pre and post D-dimer on your patients and see what you find. Also, there was an increased incidence of appendicitis during the study.
Of note, out of the almost 19,000 in the vaccine group, the median age m/f was 50/51, with only 4% being >75 yrs old and 53% having no comorbidities. This, as you know, does not match the at risk groups at all.
In order to issue an EUA, 2 basic things must be present: an emergency and no other potential treatment. Now, look back over the last 18 months and see how often any mention of potential treatment was immediately shot down and is now being censored. Why?
https://cdn.pfizer.com/pfizercom/202011/C4591001_Clinical_Protocol_Nov2020.pdf
https://www.fda.gov/media/144416/download
Am early un-blinding occurred with letters sent to the Phase-3 placebo participants, informing them of the placebo with an offer to take the gene therapy shot, which I believe 78% did cross over. This blurring of the lines further cloud any data from the trials.
Comments
Post a Comment